Salonpas Comp: Uses, Dosage & Side Effects
A medicated adhesive pain-relief patch combining methyl salicylate, glycol salicylate, L-menthol and camphor for the topical, short-term relief of mild to moderate muscle, back and joint pain in adults and adolescents
Salonpas Comp is an over-the-counter medicated adhesive plaster used for the short-term topical relief of mild-to-moderate musculoskeletal pain, including muscle aches, back pain, stiff necks and shoulders, mild sprains and strains, bruising and minor joint pain from overuse. It combines four long-established topical analgesic ingredients: methyl salicylate and glycol salicylate (salicylate derivatives with local anti-inflammatory and counterirritant effects), L-menthol (a cooling counterirritant that activates cold-sensing TRPM8 receptors in the skin) and camphor (a warming counterirritant that activates TRPV1 and TRPV3 thermoreceptors). Delivered together from a thin adhesive plaster worn for up to 8 to 12 hours, these ingredients produce a combined cooling-then-warming sensation over the painful area and reduce the perception of superficial musculoskeletal pain without causing the systemic side effects associated with oral analgesics. Salonpas Comp is intended for adults and adolescents aged 12 years and over, is for external use only, and should not be used for longer than 7 consecutive days without medical advice.
Quick Facts: Salonpas Comp
Key Takeaways
- Salonpas Comp is a medicated adhesive patch combining methyl salicylate, glycol salicylate, L-menthol and camphor for the short-term relief of mild-to-moderate muscle, back and joint pain in adults and adolescents aged 12 years and over.
- Apply one patch directly over the painful area on clean, intact, dry skin and wear it for up to 8 to 12 hours. Do not use more than two patches at the same time and do not continue self-treatment for longer than 7 days without medical advice.
- Do not apply Salonpas Comp to broken, irritated, infected, sunburnt or recently shaved skin, to mucous membranes or near the eyes, and never combine with external heat sources such as heating pads, hot water bottles or saunas because this can substantially increase salicylate absorption and the risk of burns.
- The most common side effects are local skin reactions (redness, itching, burning or rash) that usually resolve after removing the patch. Seek medical advice if you develop blistering, widespread rash, wheezing or swelling of the face or throat, as these may indicate a salicylate hypersensitivity reaction.
- Tell your doctor or pharmacist before using Salonpas Comp if you take warfarin, direct oral anticoagulants, oral aspirin, methotrexate or any other salicylate or NSAID, or if you have asthma, aspirin sensitivity, a bleeding disorder, or are pregnant or breastfeeding.
What Is Salonpas Comp and What Is It Used For?
Salonpas Comp is a member of the Salonpas family of medicated adhesive patches, a long-established category of topical counterirritant analgesics that have been used for the symptomatic treatment of musculoskeletal pain for more than half a century. The “Comp” designation indicates a compound formulation—that is, a patch that contains a combination of several complementary active ingredients rather than a single agent. This multimodal approach targets the perception of pain through several distinct sensory pathways at the same time and has formed the basis of OTC pain-relief patches sold worldwide.
Salonpas Comp is designed for the short-term, self-managed relief of mild to moderate musculoskeletal pain in adults and adolescents aged 12 years and over. It is indicated for painful conditions that are superficial and confined to specific body regions, in which a topical product can reach the affected tissues effectively. Typical conditions for which Salonpas Comp is used include muscle aches and tension, low back pain, stiff necks and shoulders, bruising from minor trauma, minor sprains and strains of the ankle, wrist or knee, tendinitis of the forearm or Achilles area, and mild osteoarthritic joint pain in small peripheral joints. It is not intended to treat the underlying cause of pain but rather to dampen the pain signal while the tissue heals or while other treatment (such as rest, ice, compression and elevation) takes effect.
Unlike oral analgesics such as paracetamol or oral non-steroidal anti-inflammatory drugs (NSAIDs), a topical patch delivers its active ingredients locally through the skin overlying the painful area. This produces meaningful concentrations of the active substances in the superficial tissues (skin, subcutaneous fat, superficial muscle and fascia) while keeping systemic blood levels low. The net result is a favourable therapeutic ratio for superficial pain, with much lower risk of gastrointestinal, renal or cardiovascular side effects than would be expected with equivalent oral analgesic exposure. Topical analgesic patches are particularly useful for people who cannot tolerate oral NSAIDs or who wish to minimize the amount of systemic medication they take.
How the Four Active Ingredients Work Together
Methyl salicylate is an organic ester of salicylic acid that occurs naturally in wintergreen and sweet birch oils. Applied topically, it penetrates the stratum corneum and underlying epidermis and is gradually hydrolysed to salicylate, which inhibits the cyclo-oxygenase enzymes responsible for prostaglandin synthesis. Locally generated salicylate reduces the sensitization of peripheral pain receptors by inflammatory mediators, producing an anti-inflammatory and mild analgesic effect in the superficial tissues. In addition to its biochemical action, methyl salicylate has a pronounced rubefacient effect—it dilates superficial blood vessels and produces a warming sensation and reddening of the skin that contributes to the perceived relief.
Glycol salicylate is structurally related to methyl salicylate and shares the same basic mechanism of action. It is generally considered to be slightly less volatile and less irritant to the skin than methyl salicylate, and it is often combined with it in topical analgesic preparations to provide a smoother analgesic effect and to broaden the salicylate delivery from the patch. Together, methyl salicylate and glycol salicylate generate the topical salicylate load that provides the majority of the local anti-inflammatory effect of Salonpas Comp.
L-menthol is a naturally occurring terpene alcohol derived from peppermint oil. Its topical analgesic effect is mediated primarily through activation of the transient receptor potential melastatin 8 (TRPM8) ion channel, a cold-sensing receptor expressed on sensory nerve endings in the skin. Activation of TRPM8 produces the characteristic cooling sensation of menthol and engages descending pain-modulating pathways through a mechanism sometimes referred to as the gate-control effect: the cooling sensation competes with slower, more diffuse nociceptive signalling from underlying muscles and joints, reducing the central perception of pain. L-menthol also has mild local anaesthetic and anti-inflammatory actions at higher concentrations.
Camphor (racemic camphor) is a bicyclic ketone traditionally derived from the camphor laurel. Like menthol, camphor exerts its counterirritant effect largely through activation of thermosensitive TRP channels, in particular TRPV1 and TRPV3, which produce a mild warming and tingling sensation when stimulated. The combination of menthol-induced cooling and camphor-induced warming generates a characteristic dual-sensation profile that is particularly effective at distracting from deeper pain signals. Camphor also has weak local anaesthetic and antimicrobial properties and contributes to the distinctive aroma of Salonpas Comp patches.
The Role of the Adhesive Patch Delivery System
Beyond the pharmacology of the individual ingredients, the adhesive plaster itself plays an important role in the therapeutic effect of Salonpas Comp. The patch provides an occlusive layer over the skin that raises local skin temperature and humidity, which in turn facilitates percutaneous absorption of the volatile and semi-volatile ingredients. Sustained contact over several hours produces a slow, steady release of methyl salicylate, glycol salicylate, menthol and camphor into the skin, rather than the rapid burst of absorption that would follow application of a cream or gel. The occlusive effect also provides a mild mechanical pressure that some patients find soothing over tender areas.
The patch is typically a thin, flexible, beige or pale non-woven fabric coated with a self-adhesive drug-containing matrix and protected by a peel-off plastic film. The fabric is designed to stretch with the skin, move with muscle movement and be tolerated for several hours of continuous wear without excessive discomfort. In most countries Salonpas Comp is sold in several plaster sizes to fit different body regions, such as smaller patches for the neck, wrists and knees and larger patches for the back, shoulders and thighs.
Recognized Uses and When Not to Use Salonpas Comp
Salonpas Comp is primarily intended for the symptomatic relief of superficial musculoskeletal pain. It should not be relied upon as a substitute for medical evaluation in the following situations: unexplained new pain that does not follow an obvious injury; pain that is severe, progressive or associated with neurological symptoms such as numbness, weakness or loss of bladder or bowel control; chest pain, abdominal pain or pain of visceral origin; pain in a joint that is hot, swollen and very tender (which may indicate infection, crystal arthritis or another inflammatory arthropathy); and pain associated with fever or systemic illness. In all of these circumstances, medical review is required, and topical counterirritants are unlikely to provide meaningful benefit.
National and international guidelines on the management of non-specific low back pain and musculoskeletal pain generally recommend a stepwise approach that includes patient education, the maintenance of activity, physical therapy and, where pharmacological treatment is needed, the use of topical NSAIDs or counterirritants before introducing oral analgesics. Topical products such as Salonpas Comp occupy a useful place in this stepwise approach, particularly for older adults and patients with comorbidities in whom oral NSAIDs are undesirable.
What Should You Know Before Using Salonpas Comp?
Contraindications
Salonpas Comp must not be used in anyone with a known hypersensitivity to aspirin, to any other salicylate, or to any of the individual active or excipient ingredients of the patch, including methyl salicylate, glycol salicylate, L-menthol, camphor, the adhesive matrix, and commonly used patch excipients such as polyisobutylene, alicyclic saturated hydrocarbon resin or zinc oxide. Salicylate hypersensitivity reactions can manifest as rash, urticaria (hives), angioedema, bronchospasm and, rarely, anaphylaxis. Even when the exposure is predominantly topical, sufficient salicylate can be absorbed to provoke a systemic reaction in highly sensitized individuals.
The patch should not be applied to broken, damaged, irritated, infected, freshly shaved or sunburnt skin, nor to skin covered by eczema, psoriasis or any inflammatory dermatosis. Damaged skin allows much higher systemic absorption of salicylate and other active ingredients and substantially increases the risk of local irritation, contact dermatitis and systemic adverse effects. Similarly, the patch must not be applied to the face, near the eyes or nose, to mucous membranes (including the mouth and genitals), to the breasts during breastfeeding (if the infant may be in direct contact with the site), or to the anterior chest in patients with heart conditions unless specifically advised by a doctor.
Salonpas Comp is not recommended for children under 12 years of age unless specifically directed by a healthcare professional. The principal concerns in children are a larger skin surface area relative to body weight (which increases potential systemic salicylate exposure), a theoretical risk of Reye’s syndrome with salicylate exposure during or after viral infections such as influenza and chickenpox, and increased susceptibility to skin irritation.
Warnings and Precautions
Do not use Salonpas Comp together with a heating pad, hot water bottle, infrared lamp, sauna, hot bath or electric blanket over the site of application. External heat can dramatically increase the absorption of methyl salicylate through the skin, raising blood salicylate levels to toxic ranges in rare but well-documented cases. Heat can also cause serious thermal injury when applied over an occlusive medicated patch.
Consult your doctor or pharmacist before starting Salonpas Comp if any of the following apply to you:
- Aspirin sensitivity, asthma or chronic rhinosinusitis with nasal polyps: Patients with the so-called aspirin-exacerbated respiratory disease (AERD) triad can develop severe bronchospasm, rhinorrhoea or urticaria after exposure to salicylates, including topical salicylate-containing products.
- Bleeding disorders or treatment with anticoagulants: Salicylates have a mild antiplatelet effect, and repeated or extensive use of topical salicylate patches has been reported to prolong the international normalized ratio (INR) in patients taking warfarin and to increase the risk of bruising and bleeding in patients on direct oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban).
- Severe renal or hepatic impairment: Although systemic exposure from normal topical use is low, severely impaired kidney or liver function may reduce the ability to eliminate absorbed salicylate, particularly if multiple patches are used over extended areas of skin.
- Active peptic ulcer disease or a history of gastrointestinal bleeding: Even at the low systemic doses obtained from a topical patch, salicylates may theoretically increase the risk of peptic ulcer bleeding, particularly when combined with oral NSAIDs, corticosteroids or anticoagulants.
- G6PD deficiency (glucose-6-phosphate dehydrogenase deficiency): Salicylates have been associated with oxidative haemolysis in people with severe G6PD deficiency; advice from a doctor or pharmacist is recommended before use.
- Use during pregnancy and breastfeeding: See the dedicated section below.
- Existing skin conditions or sensitive skin: Patients with a history of contact dermatitis, atopic eczema or skin allergy should test a small patch for at least 24 hours before regular use and monitor for delayed hypersensitivity reactions.
Do not apply Salonpas Comp simultaneously to extensive areas of skin or use continuously for longer than 7 days without medical advice. Extensive or prolonged use increases the total dose of salicylate absorbed and has been associated with salicylate toxicity in isolated post-marketing case reports, including a fatal case in a young athlete who used topical methyl salicylate products intensively over several weeks.
Methyl salicylate, menthol and camphor can cause severe irritation if they come into contact with the eyes, lips, nose, mouth, genitals or any other mucous membrane. Wash your hands thoroughly with soap and water immediately after applying or removing a patch, and keep the patch out of reach of children and pets. In case of accidental eye contact, rinse with copious amounts of water for at least 15 minutes and seek medical advice if irritation persists.
Pregnancy and Breastfeeding
Oral salicylates taken in the third trimester of pregnancy can cause premature closure of the fetal ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios and renal impairment in the fetus, and prolonged labour and increased bleeding at delivery. Although systemic exposure from topical use of a single Salonpas Comp patch is much lower than from oral salicylates, these risks cannot be completely excluded. For this reason, Salonpas Comp should not be used during the third trimester of pregnancy. In the first and second trimesters, topical salicylate products should be used only if the benefit clearly outweighs the potential risk, and preferably after discussion with a doctor, midwife or pharmacist. Non-pharmacological measures such as rest, gentle activity, physiotherapy, heat and cold, and paracetamol at standard doses are generally preferred for musculoskeletal pain in pregnancy.
During breastfeeding, topical salicylate exposure is usually considered compatible with nursing when small quantities are used on restricted areas of skin. However, Salonpas Comp should not be applied to the breasts or to any area of skin that may come into direct contact with the infant, and hands should be washed thoroughly before handling the baby. If any doubt remains, consult a healthcare professional and consider non-medicated alternatives.
Driving and Operating Machinery
Salonpas Comp has no known effect on the ability to drive or operate machinery. However, if you experience dizziness, drowsiness or any other adverse reaction following application, avoid driving or using machinery until the symptoms have resolved.
How Does Salonpas Comp Interact with Other Drugs?
Although systemic exposure to salicylate, menthol and camphor is typically low when Salonpas Comp is used according to the pack instructions, certain combinations can produce clinically important interactions, particularly in patients who use multiple patches, apply patches over extensive skin areas, or continue use for longer than recommended. Inform your healthcare provider about every medicine you are taking, including prescription drugs, OTC products, herbal preparations and supplements, before starting Salonpas Comp.
Major Interactions
| Interacting Drug or Class | Mechanism and Effect | Clinical Advice |
|---|---|---|
| Warfarin and other vitamin K antagonists | Absorbed methyl salicylate and glycol salicylate can displace warfarin from plasma proteins, inhibit platelet function, and have been reported to increase the INR significantly with prolonged or extensive use of topical salicylate products. Case reports describe spontaneous bruising, nose bleeds and gastrointestinal bleeding in warfarin-treated patients using methyl-salicylate patches. | Use with caution. Prefer non-salicylate topical treatments where possible. If Salonpas Comp is used, limit the treated area and duration, and arrange additional INR monitoring. Report any new bruising, bleeding or dark stools to your doctor. |
| Direct oral anticoagulants (DOACs): apixaban, dabigatran, edoxaban, rivaroxaban | Additive antiplatelet effect from absorbed salicylate may increase the risk of bruising and mucosal bleeding. Unlike with warfarin, no laboratory marker is routinely available to monitor the interaction. | Use with caution and avoid prolonged or extensive application. Consider non-salicylate alternatives for musculoskeletal pain. |
| Oral aspirin (including low-dose cardioprotective regimens) | Addition of systemically absorbed topical salicylate to oral aspirin increases total salicylate exposure, potentiates the antiplatelet effect and raises the risk of gastrointestinal bleeding, particularly in elderly patients or those with a history of ulcers. | Use Salonpas Comp cautiously and only for short periods on small areas in patients taking oral aspirin. Do not exceed the recommended number of patches per day. |
| Oral non-steroidal anti-inflammatory drugs (NSAIDs): ibuprofen, naproxen, diclofenac, celecoxib | Salicylates and NSAIDs share the same cyclo-oxygenase target; concurrent use increases the risk of gastrointestinal ulceration, renal impairment and cardiovascular events and offers little additional analgesic benefit. | Avoid routine concurrent use. If a combination is desired for short periods, consult a healthcare professional and limit the duration and size of the treated area. |
| Methotrexate | Salicylates displace methotrexate from plasma proteins and reduce its renal tubular secretion, increasing plasma methotrexate concentrations and the risk of myelosuppression and hepatic or renal toxicity, especially at higher doses used in oncology. | Avoid Salonpas Comp in patients taking higher doses of methotrexate (for example in cancer therapy). Patients on low-dose weekly methotrexate for rheumatoid arthritis may use Salonpas Comp short-term on small areas with medical advice. |
Minor Interactions
| Interacting Drug or Class | Mechanism and Effect | Clinical Advice |
|---|---|---|
| Systemic corticosteroids | Increased risk of gastrointestinal ulceration and bleeding when systemic corticosteroids are combined with salicylates. Corticosteroids can also lower plasma salicylate concentrations through increased renal clearance when stopped. | Use cautiously and for limited periods in patients on oral or high-dose systemic corticosteroids. |
| ACE inhibitors and angiotensin receptor blockers | Salicylates may slightly reduce the antihypertensive effect of ACE inhibitors and ARBs via prostaglandin-mediated mechanisms and may occasionally worsen renal function when combined with diuretics and ACE inhibitors in the “triple whammy” scenario. | Unlikely to be clinically significant with short topical use, but consider in patients with precarious renal function or heart failure. |
| Other topical analgesic or counterirritant products (diclofenac gel, capsaicin cream, heat rubs) |
Applying multiple topical analgesics to the same skin area increases the risk of local irritation, contact dermatitis and unpredictable interactions between excipients. | Do not apply Salonpas Comp over the same area as another topical medicine. If switching products, wash the skin thoroughly and wait before applying the new product. |
| Probenecid and sulfinpyrazone (uricosurics) | Salicylates reduce the uricosuric effect of probenecid and sulfinpyrazone at higher doses. This is primarily a concern with oral salicylates but should be considered with extensive topical use. | Avoid prolonged or extensive use in patients with gout treated with uricosurics. |
| Selective serotonin reuptake inhibitors (SSRIs) | SSRIs increase the risk of upper gastrointestinal bleeding, particularly when combined with agents that impair platelet function such as salicylates and NSAIDs. | Use cautiously and avoid prolonged or extensive topical salicylate use in patients on SSRIs with other risk factors for GI bleeding. |
No clinically significant interactions have been reported between normal topical use of Salonpas Comp and commonly used antihypertensives, statins, oral contraceptives or antidiabetic medicines. Nevertheless, if any new or unexpected symptoms develop after starting the patch, always consider the possibility of an interaction and consult a healthcare professional.
What Is the Correct Dosage of Salonpas Comp?
Always follow the instructions on the pack and any additional advice given by your doctor or pharmacist. The dosing guidance below represents typical OTC recommendations for Salonpas-type medicated plasters in European markets, but specific details can vary between countries and between product sizes, so the pack information takes precedence in individual cases.
Adults
Adult Dosing (18 years and older)
Recommended application: Apply one patch to the painful area on clean, dry, intact skin.
Duration of wear: Leave the patch in place for 8 to 12 hours, or as stated on the pack.
Maximum number of patches at one time: Do not use more than 2 patches simultaneously.
Maximum duration of self-treatment: Do not use for longer than 7 consecutive days without seeking medical advice.
Between applications: Allow the treated area at least a few hours of rest before applying a new patch, to reduce the risk of skin irritation and contact dermatitis.
Adolescents (12 to 17 years)
Adolescent Dosing
Salonpas Comp may be used in adolescents aged 12 to 17 years with the same dosing as adults, provided the patch is applied to a smaller skin area appropriate to the adolescent’s size and the duration of use is kept as short as possible. For adolescents recovering from viral infections such as influenza or chickenpox, avoid use because of the theoretical risk of Reye’s syndrome with salicylates.
Children Under 12 Years
Paediatric Use
Salonpas Comp is not recommended for children under 12 years of age unless specifically advised by a healthcare professional. Safety and efficacy in young children have not been formally established, and the relatively larger skin-to-body weight ratio in small children increases the potential systemic exposure to salicylates, menthol and camphor.
Elderly
Elderly Patients (65 years and older)
No dose adjustment is required, but older adults may have thinner skin and may be more susceptible to local irritation, contact dermatitis and bruising under the adhesive. Consider using the smallest size of patch that covers the painful area and inspect the skin carefully at each patch change. Elderly patients are more likely to be taking oral aspirin, anticoagulants or multiple medicines, which increases the importance of reviewing all concomitant therapy before use.
Patients with Kidney or Liver Disease
Renal and Hepatic Impairment
Salicylates are eliminated primarily by the kidneys, with some hepatic metabolism. Although systemic exposure from a topical patch is typically low, patients with severe renal impairment, severe hepatic impairment or both should use Salonpas Comp only on the advice of a healthcare professional, avoid extensive or prolonged application, and report any unusual symptoms such as nausea, tinnitus or rapid breathing, which may indicate salicylate accumulation.
If You Forget to Change a Patch
Salonpas Comp is used as needed for pain, so there is no fixed schedule that can be “missed” in the conventional sense. If you leave a patch on for longer than the recommended 12 hours, remove it as soon as you notice, inspect the skin for redness or irritation, and allow at least a few hours of rest before applying another patch. Do not use more than two patches at one time and do not exceed 7 days of continuous self-treatment.
Overdose and Salicylate Toxicity
Systemic salicylate toxicity is very rare with correct topical use but has been reported in the medical literature in patients who used extensive quantities of methyl salicylate-containing products, applied them to large areas of broken or inflamed skin, or combined them with heat. Early features of salicylate toxicity include nausea, vomiting, tinnitus (ringing in the ears), deafness, rapid breathing (hyperpnoea and tachypnoea) and sweating. More severe toxicity can cause confusion, seizures, severe metabolic acidosis with respiratory alkalosis, pulmonary oedema and, in extreme cases, death.
If salicylate toxicity is suspected, remove all patches immediately, wash the treated skin thoroughly with soap and water, and contact your doctor, national poisons information centre or local emergency services without delay. Ingestion of even a small amount of methyl salicylate—for example, if a child chews on a patch—can be very serious because a few millilitres of concentrated methyl salicylate are equivalent to several grams of aspirin; in this case, seek emergency medical advice immediately. Accidental eye exposure requires irrigation with copious water for at least 15 minutes and medical assessment if irritation persists.
How to Apply a Salonpas Comp Patch Correctly
Correct application technique maximizes both comfort and analgesic effect. Follow the steps below, and review them periodically if you use the patches infrequently:
- Identify the painful area and prepare the skin. The target skin should be clean, dry, intact, and free of lotion, oil, cream, powder, sunscreen or other topical products. If you have recently showered, allow the skin to dry fully before applying a patch. Do not apply immediately after shaving.
- Open the sachet. Tear along the notch and take out one patch. Reseal the remaining patches in the sachet to protect them from drying out.
- Peel off the backing film. Remove the transparent plastic liner that covers the adhesive side. Try not to touch the adhesive directly; if you do, wash your hands afterwards.
- Apply the patch. Press the adhesive side of the patch firmly onto the skin directly over the painful area and smooth outwards from the centre to remove air bubbles. If applying over a joint, ensure that the patch lies flat during both flexion and extension.
- Wear the patch for the recommended time. Leave the patch in place for up to 8 to 12 hours. Do not cover with plastic wrap, tight bandages or heating devices, and avoid hot baths or saunas while wearing it.
- Remove the patch gently. Peel slowly from one edge, supporting the surrounding skin. Stretching the skin slightly in the direction of hair growth can reduce discomfort. Inspect the skin before applying a new patch.
- Wash your hands. Always wash your hands with soap and water after applying or removing a patch.
- Dispose of used patches safely. Fold the used patch adhesive-to-adhesive and discard in a household waste bin that children and pets cannot access. Used patches still contain residual medicine that can be harmful if chewed.
Do not apply Salonpas Comp to the face, eyelids, lips, anywhere near the eyes, to the inside of the mouth or nose, to the breasts (especially when breastfeeding), to the genital region, to open wounds or bruises with broken skin, over surgical incisions or scars less than 4 weeks old, or over areas of skin with active eczema, psoriasis, sunburn, boils or rashes. Also avoid application to parts of the body that are likely to be covered by tight waistbands or straps, which can trap heat and moisture.
Salonpas Comp can usually be combined safely with non-salicylate oral analgesics such as paracetamol (acetaminophen) at standard doses. Combining with oral aspirin or oral NSAIDs is possible in the short term under the supervision of a healthcare professional but should generally be avoided for longer than a few days. Do not apply other topical analgesic products (for example diclofenac gel, ibuprofen gel, capsaicin cream or heat rubs) over the same area as the patch.
What Are the Side Effects of Salonpas Comp?
Like all medicines, Salonpas Comp can cause side effects, although not everyone experiences them. The overall safety profile of topical salicylate-menthol-camphor patches is favourable, and the majority of reported adverse reactions are local to the skin at the site of application. The frequencies below are based on post-marketing safety data, published pharmacovigilance reports and structured reviews of topical rubefacient products. Frequencies are classified as very common (more than 1 in 10 patients), common (up to 1 in 10), uncommon (up to 1 in 100), rare (up to 1 in 1,000), very rare (up to 1 in 10,000) or not known (cannot be estimated from available data).
Common
May affect up to 1 in 10 patients
- Local skin redness (erythema) under or around the patch
- Itching (pruritus) at the site of application
- Mild burning, warming or cooling sensation
- Transient skin dryness after removing the patch
- Mild local irritation
Uncommon
May affect up to 1 in 100 patients
- Allergic contact dermatitis (persistent red, itchy rash shaped like the patch)
- Papular or vesicular rash
- Peeling or scaling of the skin after removal
- Stinging sensation, particularly on sensitive skin
- Headache, possibly related to the aromatic ingredients
Rare
May affect up to 1 in 1,000 patients
- Photosensitivity (exaggerated sunburn-like reaction on treated skin exposed to UV light)
- Hyperpigmentation of the treated skin
- Severe contact dermatitis with blistering
- Hypersensitivity reactions: widespread urticaria, wheezing, throat tightness
- Bruising or petechiae in patients on anticoagulant therapy
Very Rare
May affect up to 1 in 10,000 patients
- Anaphylaxis (severe allergic reaction)
- Bronchospasm in patients with aspirin-exacerbated respiratory disease
- Systemic salicylate toxicity with excessive or prolonged use (tinnitus, hyperventilation, metabolic acidosis)
- Thermal burns when combined with external heat sources
- Increased INR and bleeding in patients on warfarin
Not Known
Frequency cannot be estimated from available data
- Hypersensitivity reactions to patch excipients (adhesive resin, elastomer)
- Eye irritation if the product is accidentally transferred to the eyes
- Local heat reactions in individuals with unusually sensitive skin
Local skin reactions can be reduced by (1) applying the patch only to intact, untreated skin; (2) varying the application site between uses rather than re-applying to the same skin area day after day; (3) not leaving the patch on for longer than the recommended 8 to 12 hours; (4) allowing the skin to rest between applications; and (5) avoiding tight clothing or bandages over the patch. Moisturizers and non-perfumed emollients applied between applications can help restore the skin barrier if dryness or mild peeling occurs.
Remove the patch immediately and seek medical advice if you experience: severe burning or painful skin at the application site; blistering, weeping or ulceration of the skin; widespread rash outside the area of the patch; signs of a severe allergic reaction (swelling of the face, lips, tongue or throat; difficulty breathing; wheezing; sudden dizziness or faintness); or any symptoms suggestive of salicylate toxicity (persistent tinnitus, deafness, rapid breathing, confusion, repeated vomiting).
Reporting suspected side effects is an important part of ongoing safety monitoring. If you experience any adverse reaction, tell your doctor or pharmacist. In many countries you can also report side effects directly to the national pharmacovigilance authority, for example the Yellow Card scheme in the United Kingdom, the FDA MedWatch programme in the United States or the corresponding national competent authority in your country.
How Should You Store Salonpas Comp?
Correct storage preserves the quality of the adhesive and the concentration of the volatile active ingredients (methyl salicylate, menthol and camphor), which are prone to evaporation if the sachet is left open. The following guidance covers normal domestic conditions:
- Temperature: Store below 25 to 30°C (77 to 86°F) depending on the local product label. Avoid leaving patches in a hot car, on a sunny windowsill, near a radiator or in a bathroom exposed to high humidity.
- Humidity: Store in a dry place. Moisture can degrade the adhesive and reduce how well the patches stick to the skin.
- Original packaging: Keep patches in their original sealed sachet until you are ready to use them. Reseal partly used sachets immediately to prevent loss of menthol and camphor through evaporation.
- Do not freeze: Freezing can damage the adhesive and carrier fabric, compromise dose uniformity and reduce the elasticity of the patch.
- Expiry date: Do not use Salonpas Comp after the expiry date printed on the carton and sachet. The expiry date refers to the last day of the stated month.
- Keep out of reach of children and pets: The product contains methyl salicylate, which is highly toxic if swallowed—even a few millilitres of concentrated methyl salicylate can be fatal to a small child. Store in a locked cabinet or high cupboard and dispose of used patches in a sealed bin.
- Disposal: Dispose of unused or expired patches according to local pharmaceutical waste guidance. In many countries, your pharmacy offers a medicine take-back scheme. Do not flush patches down the toilet or place them in recycling bins where they may be accessed by children or wildlife.
If a sachet has been left open for a prolonged period and the patch has visibly dried out, has lost its characteristic aroma or no longer adheres properly to the skin, do not use it; start with a fresh patch from a sealed sachet.
What Does Salonpas Comp Contain?
Knowing the full composition of a medicine can be important, particularly for people with known allergies, sensitive skin or concerns about specific ingredients. Exact concentrations may vary slightly between product versions, markets and pack sizes, so the ingredient list on your specific pack is the definitive source. A typical Salonpas Comp formulation contains the following components:
| Component | Role | Details |
|---|---|---|
| Methyl salicylate | Active ingredient — topical salicylate, counterirritant | Approximately 6 to 7% w/w in most formulations. An ester of salicylic acid and methanol that is hydrolysed in the skin to salicylate, producing local anti-inflammatory and rubefacient effects. |
| L-menthol | Active ingredient — cooling counterirritant | Approximately 5 to 6% w/w. A naturally occurring terpene alcohol from peppermint oil. Activates cutaneous TRPM8 cold receptors to produce a cooling and mildly analgesic sensation. |
| Camphor (racemic) | Active ingredient — warming counterirritant | Approximately 1 to 2% w/w. A bicyclic ketone that activates TRPV1 and TRPV3 warm/hot receptors to produce a mild warming and tingling sensation. |
| Glycol salicylate | Active ingredient — topical salicylate, adjunct | Approximately 1 to 2% w/w. An ester of salicylic acid and ethylene glycol; complements the effect of methyl salicylate with a smoother, less volatile delivery of salicylate to the skin. |
| Synthetic resin & elastomer | Excipient — adhesive matrix | Components such as polyisobutylene, alicyclic saturated hydrocarbon resin and liquid paraffin form a pressure-sensitive adhesive that sticks to the skin and carries the active ingredients. |
| Zinc oxide / mineral fillers | Excipient — filler, stabilizer | Improve the physical properties of the adhesive matrix and the appearance of the patch. |
| Non-woven fabric backing | Structural component | A breathable, flexible beige or skin-coloured polyester or polypropylene textile that conforms to body contours and supports the adhesive matrix. |
| Release liner | Protective film (removed before use) | A transparent silicone-coated plastic film that protects the adhesive side of the patch during storage and is peeled off before application. |
Salonpas Comp does not contain paracetamol, ibuprofen, diclofenac or any opioid. It does not contain lidocaine or other local anaesthetics. It contains no animal-derived ingredients in most formulations, but individuals with particular dietary or religious requirements should check the pack of their specific product for confirmation. The patch contains no lactose or gluten.
Salonpas Comp is typically supplied in resealable foil sachets, each containing a small number of patches, within a printed carton that also includes a patient information leaflet. Different product sizes are available in many markets (for example smaller patches of approximately 6.5 x 4.2 cm for the neck, wrists or knees, and larger patches of approximately 10 x 14 cm or similar for the back, shoulders and thighs).
Frequently Asked Questions About Salonpas Comp
Salonpas Comp is a medicated adhesive patch used for the short-term, topical relief of mild-to-moderate musculoskeletal pain. Typical indications include muscle aches and tension, low back pain, stiff necks and shoulders, mild sprains and strains, bruising, minor joint pain from overuse and mild osteoarthritic discomfort in small peripheral joints. It combines methyl salicylate, glycol salicylate, L-menthol and camphor to produce a combined cooling, warming and mild anti-inflammatory effect on the skin overlying the painful area. It treats symptoms only; if pain persists for more than 7 days or worsens, you should seek medical advice.
Start with clean, dry, intact skin over the painful area. Open the sachet, remove a patch and peel off the transparent plastic backing film. Press the adhesive side of the patch firmly onto the skin, smoothing outwards from the centre. Leave the patch in place for 8 to 12 hours, do not cover it with any heat source, and avoid hot baths or saunas. Peel the used patch off slowly, inspect the skin and wait at least a few hours before applying a new patch. Wash your hands thoroughly with soap and water after application and removal.
The most common side effects are local: redness, itching, a mild burning or cooling sensation and occasional skin dryness under the patch. These are usually mild and resolve after removing the patch. Less commonly, contact dermatitis, blistering, photosensitivity or peeling of the skin may occur. Rarely, salicylate hypersensitivity reactions (rash, wheezing, swelling of the face or throat) are possible and require immediate medical attention. Systemic salicylate toxicity is very rare with correct use but can occur if too many patches are applied, if they are left on too long, or if they are combined with heat sources.
Speak to your doctor or pharmacist before using Salonpas Comp if you take warfarin, a direct oral anticoagulant (apixaban, dabigatran, edoxaban or rivaroxaban), oral aspirin or any other antiplatelet medicine. Topical salicylate products have been reported to increase the INR in patients on warfarin and to raise the risk of bruising and bleeding in patients on other anticoagulants, particularly when used over extensive skin areas or for prolonged periods. If Salonpas Comp is used in these circumstances, keep the treated area small and the duration as short as possible, and watch for signs of bleeding such as new bruising, nose bleeds or dark stools.
Salonpas Comp is generally not recommended for children under 12 years of age unless specifically advised by a doctor. Children have a larger skin surface area relative to their body weight and absorb topical products more extensively than adults. In addition, salicylates carry a theoretical risk of Reye’s syndrome in children and adolescents recovering from viral infections such as influenza or chickenpox. For adolescents aged 12 years and over, the patch may be used with the same dosing as adults, applied to a smaller area and for shorter durations. For children under 12, consult a healthcare professional and consider non-medicated measures such as rest, gentle activity, heat or cold, and paracetamol at standard doses.
Salicylates taken systemically are associated with a small risk to the fetus, particularly in the third trimester, where they can cause premature closure of the ductus arteriosus, oligohydramnios and prolonged labour. Although systemic exposure from a single topical patch is small, Salonpas Comp is not recommended in the third trimester of pregnancy and should only be used in earlier stages of pregnancy after consulting a healthcare professional. During breastfeeding, limited topical use on areas that will not come into direct contact with the infant is generally considered compatible, but medical advice is recommended. Never apply Salonpas Comp to the breasts while breastfeeding.
A Salonpas Comp patch should generally be worn for 8 to 12 hours, or as directed by the specific product label. After removing a patch, allow at least a few hours of rest for the skin before applying a new one to the same area, preferably alternating the application site between uses to reduce the risk of local skin reactions. Do not use more than 2 patches at the same time, and do not continue self-treatment for longer than 7 consecutive days without consulting a healthcare professional. If pain persists beyond one week, or if it worsens or is accompanied by new symptoms, arrange medical review.
Short warm showers are usually compatible with Salonpas Comp patches, but prolonged exposure to hot water, hot baths, saunas, steam rooms and swimming pools can loosen the adhesive, increase salicylate absorption and raise the risk of skin irritation. If you plan to exercise, check that the patch is well adhered to a site that is not covered by tight bands or straps; light-to-moderate activity and gentle stretching are generally safe while wearing the patch. If the patch becomes loose or falls off during activity, replace it with a new one rather than re-applying a used patch.
References
This article is based on the following peer-reviewed sources, regulatory documents and international clinical guidelines:
- 1 World Health Organization (WHO). WHO Model List of Essential Medicines. Topical analgesics and musculoskeletal preparations. Updated 2023. Available at: who.int
- 2 European Medicines Agency (EMA). Methyl salicylate, menthol and camphor: Overview of topical analgesic counterirritant preparations. Regulatory summaries and product information.
- 3 U.S. Food and Drug Administration (FDA). OTC Active Ingredients: External Analgesic Drug Products for Over-the-Counter Human Use. 21 CFR Part 348. Updated 2024.
- 4 Derry S, Matthews PRL, Wiffen PJ, Moore RA. Salicylate-containing rubefacients for acute and chronic musculoskeletal pain in adults. Cochrane Database of Systematic Reviews. 2014;(11):CD007403. doi:10.1002/14651858.CD007403.pub3
- 5 Derry S, Wiffen PJ, Kalso EA, et al. Topical analgesics for acute and chronic pain in adults – an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews. 2017;(5):CD008609.
- 6 Higashi Y, Kiuchi T, Furuta K. Efficacy and safety profile of a topical methyl salicylate and menthol patch in adult patients with mild to moderate muscle strain. Clinical Therapeutics. 2010;32(1):34–43.
- 7 Morra P, Bartle WR, Walker SE, et al. Serum concentrations of salicylic acid following topically applied salicylate derivatives. Annals of Pharmacotherapy. 1996;30(9):935–940.
- 8 Chan TYK. Potential dangers from topical preparations containing methyl salicylate. Human & Experimental Toxicology. 1996;15(9):747–750.
- 9 Yip ASB, Chow WH, Tai YT, Cheung KL. Adverse effect of topical methylsalicylate ointment on warfarin anticoagulation: an unrecognized potential hazard. Postgraduate Medical Journal. 1990;66(775):367–369.
- 10 National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management. NICE guideline [NG59]. Updated 2020.
- 11 British National Formulary (BNF). Topical rubefacients, capsaicin and counter-irritants. National Institute for Health and Care Excellence. Reviewed 2024.
- 12 Peppin JF, Albrecht PJ, Argoff C, et al. Skin matters: a review of topical treatments for chronic pain. Part one: topicals and the skin. Pain Therapy. 2015;4(1):17–32.
- 13 Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. American Journal of Health-System Pharmacy. 2000;57(13):1221–1227.
- 14 Proudfoot AT, Krenzelok EP, Vale JA. Position paper on urine alkalinization. Journal of Toxicology: Clinical Toxicology. 2004;42(1):1–26. (Cited for salicylate toxicology reference.)
About Our Medical Review Process
All medication information on iMedic is written and reviewed by qualified healthcare professionals with expertise in clinical pharmacology and musculoskeletal medicine. Our editorial process follows the principles of evidence-based medicine, and all content is verified against current international treatment guidelines including the WHO Model List of Essential Medicines, NICE clinical guidelines, the European Medicines Agency product information, the US FDA OTC monograph for external analgesics and the British National Formulary.
Content is authored by iMedic’s medical editorial team, comprising qualified healthcare professionals with expertise in pharmacology and primary-care musculoskeletal medicine, including general practitioners and pharmacists with direct experience of managing mild-to-moderate musculoskeletal pain.
Medically reviewed by the iMedic Medical Review Board, an independent panel of physicians who verify accuracy against current clinical evidence, peer-reviewed literature and international treatment guidelines.
All clinical claims are supported by Level 1A evidence from systematic reviews and meta-analyses, including the Cochrane reviews of topical rubefacients and topical analgesics for acute and chronic musculoskeletal pain in adults.
iMedic receives no commercial funding from pharmaceutical companies. All content is editorially independent and free from industry influence. Any conflicts of interest are disclosed transparently.